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Fibrinogen plays an important role in blood coagulation but
its function extends far beyond blood clotting being involved
in inflammation and repair. Besides these crucial functions it
can also promote tissue fibrosis. To determine whether
fibrinogen is involved in the development of renal
tubulointerstitial fibrosis we utilized the profibrotic model of
unilateral ureteral obstruction in fibrinogen-deficient mice. In
the heterozygotes, obstruction was associated with a massive
deposition of intrarenal fibrinogen. Fibrinogen deficiency
provided significant protection from interstitial damage and
tubular disruption, attenuated collagen accumulation, and
greatly reduced de novo expression of a-smooth muscle actin
in the obstructed kidney. While no differences were found in
renal inflammatory cell infiltration, fibrinogen deficiency was
associated with a significant reduction in interstitial cell
proliferation, a hallmark of renal fibrosis. In vitro, fibrinogen
directly stimulated renal fibroblast proliferation in a dose-
dependent manner. This mitogenic effect of fibrinogen was
mediated by at least three different cell surface receptors on
renal fibroblasts: TLR2, TLR4, and ICAM-1. Thus, our study
suggests that fibrinogen promotes renal fibrosis by
triggering resident fibroblast proliferation.
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The primary role of the coagulation system is to prevent
blood loss after vascular injury by ensuring the formation of
stable hemostatic clots. However, the function of the
coagulation system extends far beyond blood clotting,
including such diverse processes as protection against
infection, inflammation, and tissue repair.1,2 Some of these
effects have specifically been linked to fibrinogen.3–5 Fibrino-
gen is found in plasma at a concentration of 1.5–4.5 g/l and
consists of two identical subunits that contain three polypep-
tide chains: a, b, and g.2 Cleavage by thrombin releases
fibrinopeptides A and B and converts fibrinogen into fibrin.
Activation of the coagulation cascade and the deposition of
fibrin into the provisional extracellular matrix is an integral
part of tissue injury. The fibrin-containing matrix can
promote infiltration of repair cells and can activate healing
mechanisms such as angiogenesis, reepithelialization, cell
proliferation, and wound contraction.1 However, if imbal-
anced, these wound-healing mechanisms can contribute to
excessive scar formation and organ fibrosis. Gene-targeting
studies suggest that fibrinogen might play a role in tipping the
balance between healthy wound-healing and fibrotic scarring.6
Consistent with this hypothesis, fibrinogen has been demon-
strated to promote the development of fibrosis in several
organs including pancreas, skin, and muscle.6–8
In the kidney, progressive fibrosis is the final pathway of
most chronic diseases leading to irreversible loss of renal
function.9 Fibrinogen might be a novel candidate molecule in
the development of renal fibrosis given the above-mentioned
results from other organs. Massive fibrin deposition is
commonly observed in renal biopsies in a variety of acute
and chronic kidney diseases,10–12 and experimentally it has
been shown that the lack of fibrinogen can attenuate renal
impairment in inflammatory glomerulonephritis.13 There-
fore, the aim of this study was to address the hypothesis that
fibrinogen plays a direct role in the development and
progression of renal fibrosis.
To test the impact of fibrinogen on renal fibrosis, kidneys
from fibrinogen knock-out (Fib/) and heterozygous
(Fibþ /) mice were compared at 1 or 2 weeks of unilateral
ureteral obstruction (UUO). It was found that the lack of
fibrinogen was associated with a significant protection from
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developing tubulointerstitial damage. UUO kidneys from
Fib/ mice showed significantly less deposition of extra-
cellular matrix and greatly attenuated expansion of resident
fibroblasts. In vitro, fibrinogen stimulated renal fibroblast
proliferation directly, which was mediated by at least three
different cell surface receptors.
RESULTS
Fibrinogen accumulates in UUO kidneys and associates with
tubulointerstitial damage
Consistent with published data by Yamaguchi et al.,14 we
observed a more than tenfold increase of fibrinogen by
immunoblot in UUO kidneys from wild-type mice after 7 days
of ureteral obstruction (Figure 1a). Immunoreactivity recog-
nizing both fibrinogen and fibrin was restricted to the
intravascular space in contralateral kidneys, whereas it was
massively enhanced in the tubulointerstitial space of UUO
kidneys (Figure 1b and c). To test whether fibrinogen would
contribute to the development of renal fibrosis, Fib/ mice
were subjected to UUO and compared with heterozygous
littermates. Fib/ mice had a normal phenotype under
baseline conditions and no appreciable increase in bleeding risk
or healing defects after UUO surgery. At day 14 of obstruction,
kidneys from Fibþ / animals exhibited fibrinogen deposits
throughout the entire renal interstitium (Figure 1d and e). In
some areas we found particularly intense accumulations, which
was often associated with increased tubulointerstitial damage
(Figure 1d). As expected, we found no fibrinogen in kidneys
from Fib/ mice (Figure 1f). At day 7 of UUO, both groups
showed dilated tubules with flattened epithelium and a mild
increase in interstitial volume without histologically appreci-
able differences (Figure 1g–i). At 14 days, however, loss of
tubular structures and expansion of interstitial cells and matrix
was significantly more severe in Fibþ / when compared with
Fib/mice (Figure 1i–k). Whereas tubules were often replaced
by fibrous tissue in Fibþ / kidneys, tubular structures
persisted significantly longer in Fib/ mice (Figure 1j–m).
We consistently found a significant reduction in intrarenal
collagen deposition in Fib/mice as shown by Picrosirius Red
staining (Figure 2a and b) and immunoblot (Figure 2c).
Fibrinogen deficiency has no impact on inflammatory cell
infiltration
Although their role is not completely understood,15 inflam-
matory cells infiltrating the interstitium are characteristic
features of renal fibrosis. Consistently, increased numbers of
infiltrating CD45-positive leukocytes, CD4-positive lympho-
cytes, F4/80-positive macrophages, and Ly-6B.2-positive
polymorphonuclear cells were found in UUO kidneys of
both groups. Fibrinogen deficiency however, had no impact
on the respective cell counts (Figure 2d and e).
Fibrinogen deficiency is associated with reduced numbers of
(myo)fibroblasts in UUO
a-Smooth muscle actin (a-SMA), which is used as a marker
of myofibroblasts,9 was significantly upregulated in the
tubulointerstitial space of UUO kidneys from both groups.
However, the upregulation was significantly higher in Fibþ /
animals when compared with Fib/ littermates (Figure 3a
and b). For further analysis of differences in interstitial cell
expansion, immunostainings using S100A4 were performed,
showing a massive increase in S100A4-positive cells in
Fibþ / when compared with Fib/ kidneys (Supplementary
Figure S1B online). S100A4 is widely used as a marker for
fibroblasts and myofibroblasts,16 but its specificity has been
questioned because of expression by inflammatory cells.17 We
therefore quantified only those S100A4-positive cells that
were CD45 negative (Figure 3c–e), and found that fibrinogen
deficiency was associated with significantly lower numbers
of S100A4þ /CD45 cells after 7 and 14 days of UUO
(Figure 3e). These results were further confirmed by using
ER-TR7, an independent fibroblast marker18 (Figure 3f and
g), and suggest a differential expansion of the interstitial
fibroblast population as a possible mechanism for the
profibrogenic effects of fibrinogen.
Fibrinogen deficiency is associated with reduced interstitial
cell proliferation in UUO
Proliferation of interstitial fibroblasts has been identified as a
leading mechanism in progressive renal fibrosis.19,20 In
agreement with this, we found a high rate of proliferation
in interstitial fibroblasts in UUO kidneys from both groups.
However, staining for cell cycling marker Ki67 exhibited
significantly lower rates of interstitial cell proliferation in
Fib/ kidneys when compared with Fibþ / kidneys after
7 and 14 days (Figure 4a). In contrast, no difference was
observed in the number of proliferating tubular epithelial
cells between the groups (Supplementary Figure S1C online).
These findings suggest that fibrinogen exerts a profibrogenic
effect by enhancing the proliferation of interstitial fibroblasts.
Fibrinogen directly mediates the proliferation of renal
fibroblasts in vitro
It has been previously demonstrated that fibrinogen is a
mitogen for some cell types21 but not for others.7 Using
normal rat kidney interstitial fibroblasts (NRK-49F cells), we
found that exposure to fibrinogen significantly increased cell
proliferation in a dose-dependent manner (Figure 4b). This
effect was cell-type specific, as no changes in proliferation
were observed in renal epithelial cells (mPT and IMCD3 cells;
Supplementary Figure S1D and E online). To substantiate the
observed effect, we exposed renal fibroblasts to plasma from
Fib/ and Fibþ / mice. Consistent with the first results, we
found a significantly stronger proliferation using fibrinogen-
containing plasma when compared with fibrinogen-free
plasma (Figure 4c). Collectively, these in vitro data indicate
that fibrinogen acts as a direct mitogen on renal interstitial
fibroblasts.
Fibrinogen does not promote the conversion of fibroblasts
into myofibroblasts
The transition of resting fibroblasts into active a-SMA-
positive myofibroblasts is regarded as a critical event in renal
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Figure 1 | Fibrinogen accumulates in unilateral ureteral obstruction (UUO) kidneys and fibrinogen deficiency is associated with
attenuated tubulointerstitial damage. (a) Immunoblot at 7 days of UUO in wild-type (WT) mice shows a massive increase in renal
fibrinogen (Fib) in the obstructed vs contralateral kidney. (b) Fibrinogen immunosignal is confined to the vascular space in contralateral WT
kidney, (c) but present throughout the tubulointerstitium after UUO. (d) Representative immunostaining for fibrinogen at 14 days of UUO in
Fibþ / showing outer medulla and cortex. (e) Detail from the outer medulla of the same section. (f) As expected, no fibrinogen was found
in kidneys from Fib/ mice. Representative hematoxylin/eosin stains of cortex and outer medulla from Fibþ / and Fib/ kidneys at (g, h)
7 and (j–m) 14 days of UUO. (i) At day 7, both groups showed dilated tubules with flattened epithelium but no significant difference in
tubulointerstitial damage quantification. (i–m) At 14 days, loss of tubular structures and expansion of interstitial mass was significantly more
severe in Fibþ / when compared with Fib/ mice. Original magnifications:  100 (j, k);  200 (d);  400 (b, c, f–h, l, m);  630 (e). Scale
bars represent mean values±s.e.m. *Po0.05; **Po0.01. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Kidney International (2011) 80, 1035–1044 1037
I So¨rensen et al.: Fibrinogen in renal fibrosis o r ig ina l a r t i c l e
fibrosis progression.9 In order to test whether fibrinogen
promotes the transition of fibroblasts to activated myofibro-
blasts, we evaluated the fibrinogen-dependent de novo
expression of a-SMA and fibronectin. After fibrinogen
exposure, we found no significant induction of a-SMA or
increase in fibronectin on protein (Figure 4d) or mRNA level
(data not shown). Thus, these results argue against a
significant role for fibrinogen in the conversion from
fibroblasts to myofibroblasts, but suggest an increase in the
pool of interstitial fibroblasts as the leading mechanism. The
activation into myofibroblasts requires the presence of
additional factors that are characteristic of UUO such as
transforming growth factor-b.
Fibrinogen interacts with renal fibroblasts via Toll-like
receptors and ICAM-1
Fibrinogen can interact with a variety of cell surface receptors
that are known to be expressed on fibroblasts.2 Among these,
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Figure 2 | Fibrinogen deficiency is associated with reduced collagen accumulation. (a, a’) Representative microphotographs of collagen
deposition as visualized by Picrosirius Red staining using (a) light microscopy and (a’) polarized light at 14 days of unilateral ureteral
obstruction (UUO). (b) Quantification of Picrosirius Red polarized images in cortex and outer medulla (OM). (c) Immunoblot analysis for
Collagen I using Fibþ / and Fib/ kidneys at 14 days of UUO. (d) Representative microphotographs of immunostaining for CD45.
(e) Quantification of CD45-positive leukocytes, CD4-positive lymphocytes, F4/80-positive macrophages, and Ly-6B.2-positive
polymorphonuclear cells in UUO kidneys at 7 and/or 14 days of UUO. Original magnification  400 (a, a’, d). Scale bars represent mean
values±s.e.m. *Po0.05; **Po0.01.
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the integrin receptor family and the according downstream
signaling have a well-described role in renal fibrosis.22,23
However, treatment with RGD (arginine–glycine–aspartic
acid)-containing peptides or b1-integrin antibody had no
significant impact on fibrinogen-induced proliferation (Sup-
plementary Figure S1F online). We therefore focused on the
Toll-like receptor (TLR) family that has been shown to play a
crucial role in the progression of renal fibrosis.24–26 Fibrino-
gen is a known ligand for TLR2 and TLR4 that are both
expressed on renal fibroblasts.27–29 Specific small interfering
RNA (siRNA) knockdown of TLR2 and TLR4 (knockdown
efficiency of 87 and 79%, respectively; Supplementary Figure
S1G online) resulted in a significant reduction in the
mitogenic potential of fibrinogen (Figure 5a). Similarly,
siRNA knockdown of myeloid differentiation primary-
response gene 88 (MyD88), which is the signaling adaptor
shared by TLR2 and TLR4,26 resulted in significantly reduced
proliferation (Figure 5b; siRNA knockdown efficiency of
76%; Supplementary Figure S1G online). These data were
confirmed in primary renal fibroblasts from MyD88 knock-
out mice displaying a blunted mitogenic effect after
fibrinogen exposure when compared with wild-type fibro-
blasts (Figure 5c). Although these results demonstrate an
important role for TLR-dependent signaling, the inhibition
of proliferation was only partial, suggesting additional
pathways of mitogenic activation. We therefore investigated
the role of another cell surface receptor, intercellular adhesion
molecule 1 (ICAM-1), that has previously been shown to
mediate fibrinogen-induced proliferation in lymphoma
cells21 and that has been implied in tissue fibrosis.30 After
confirming a strong expression of ICAM-1 in rat renal
fibroblasts (Supplementary Figure S1H online), we used
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Figure 3 | Fibrinogen deficiency is associated with a reduced upregulation of a-smooth muscle actin (a-SMA) and attenuated
fibroblast proliferation. (a) Representative immunostaining for a-SMA, a marker for myofibroblasts, comparing Fibþ / and Fib/ kidneys
at 14 days of unilateral ureteral obstruction (UUO). (b) Immunoblot for a-SMA at 14 days of UUO. (c, d) Representative immuno-double
staining for S100A4 and CD45. (c) Higher magnification of boxed area in d showing S100A4-positive/CD45-negative cells (arrows), CD45-
positive/S100A4-negative cells (B), and double-positive cells (asterisks). (e) S100A4-positive/CD45-negative cells were counted as
fibroblasts comparing Fibþ / and Fib/ kidneys at 14 days of UUO. (f, g) Immunostaining for fibroblast marker ER-TR7 and quantification
of ER-TR7-positive cells in UUO kidneys at 14 days. Original magnifications:  400 (a, f);  630 (c, d). Scale bars represent mean
values±s.e.m. *Po0.05.
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blocking antibodies to ICAM-1 that showed a significant
attenuation of the proliferative effect of fibrinogen (Figure 5d).
This observation was corroborated in siRNA-based ICAM-1
knockdown experiments (Figure 5e; siRNA knockdown
efficiency of 68%; Supplementary Figure S1G online). The
antimitogenic effects of TLR2, TLR4, and ICAM-1 knockdown
were additive, as shown by combined siRNA experiments
(Figure 5e). Taken together, these data suggest that fibrinogen
is involved in renal fibroblast proliferation through TLR2-,
TLR4-, and ICAM-1-dependent signaling.
DISCUSSION
In this report, we propose a novel mechanism in which
fibrinogen or its derivatives promote renal fibrosis by
enhancing renal fibroblast proliferation. This mechanism is
consistent with the concept that an enhanced proliferation of
resident interstitial fibroblasts represents a major driving
force in progressive renal fibrosis.19,20 Genetic ablation of
fibrinogen was associated with a significantly reduced
proliferation of interstitial fibroblasts and attenuated renal
damage. An important role in the development of tissue
fibrosis has been demonstrated for different components of
the coagulation system.15,31 In order to dissociate the
function of fibrinogen as a coagulation protein from its
potential function as a proproliferating factor, we performed
in vitro experiments in the absence of other coagulation
components. In vitro, fibrinogen acted as a strong mitogen,
promoting renal fibroblast expansion.
Fibrinogen exerted its mitogenic effect through at least
three different receptors: TLR2, TLR4, and ICAM-1.
Fibrinogen binding to ICAM-1 has previously been shown
to regulate various physiological and pathophysiological
processes, such as cardiomyocyte contractility,32 lymphocyte
proliferation,21 and endothelial permeability.33 Interestingly,
it has been shown that ICAM-1 is highly upregulated in
UUO34 and that its deficiency is associated with a striking
reduction in renal fibrosis progression in models of diabetic
nephropathy and nephrotoxic nephritis.35,36 Although this
protective effect of ICAM-1 deletion has been mainly
attributed to an attenuated recruitment of inflammatory
cells, our data suggest that decreased fibroblast proliferation
might have played an additional role.
The TLR family, which was originally identified as a
defense mechanism against invasion of pathogenic micro-
organisms, is increasingly recognized to play an important
role in a variety of acute and chronic renal diseases.26
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Fibrinogen is a prominent nonpathogen-derived TLR
activator that has been shown to induce diverse biological
effects through binding to TLR2 and TLR4.27,37 A large body
of evidence underlines a crucial role for TLRs in promoting
acute and chronic injury responses in the kidney.26,38
However, recent data have been conflicting with regard to
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the specific implications of TLR2 and TLR4 in promoting
renal fibrosis.24,25,29,39 Our results are consistent with two
studies showing that TLR4-deficient mice are protected from
developing renal fibrosis in UUO.24,25 Although most
previous studies have related TLR-dependent effects in renal
injury to renal epithelial cells and to infiltrating immune
cells, our data suggest a hitherto unrecognized role for TLR-
dependent signaling in the fibroblast population.
Interestingly, fibrinogen deficiency had no appreciable effect
on renal leukocyte infiltration in our model of UUO. This
finding was unexpected, given the ample data on proinflam-
matory properties of fibrinogen.2–4,40 Fibrinogen and its
degradation products are chemotactic and they can trigger
the full activation of immune cells.3 However, the impact of
fibrinogen on inflammation seems to be organ and model
specific as suggested by experiments in fibrinogen-deficient
mice showing no reduction in inflammatory cell accumulation
in bleomycin-induced lung injury.41 Our data show that
interstitial fibrin(ogen) deposition is not required for leukocyte
infiltration, but we cannot exclude that secondary pathways of
inflammation are modified by its presence.
Fibrinogen is one of the major acute-phase proteins
synthesized by the liver and its concentration is often used as
a surrogate for systemic inflammation. Moreover, circulating
fibrinogen is a well-established cardiovascular risk marker
that correlates strongly, consistently, and independently with
arteriosclerosis, myocardial infarction, and stroke.42 Similar
to the general cardiovascular risk, it has been consistently
demonstrated that higher plasma levels of fibrinogen are
associated with a more rapid decline in renal function.43,44
The current data suggest the possibility of a direct
involvement of fibrinogen in progression of kidney disease.
Therapeutic approaches to lower plasma fibrinogen concen-
tration might therefore not only have beneficial effects for the
general cardiovascular risk profile, but also for halting
progression of renal disease. This concept requires further
research to better define potential benefits but also risks of
fibrinogen-lowering interventions including negative con-
sequences such as impaired healing.
In summary, our data suggest that fibrinogen represents a
new pathophysiological activator of fibroblasts and plays an
important role in renal fibrosis. The effects of fibrinogen
seem to be mediated by a variety of receptors with an
important role of the TLR system. As renal fibrinogen
deposition is present in many forms of chronic kidney
disease, we believe that it may be an important promoter of
progressive renal fibrosis. Our observations are extending the
notion that fibrinogen plays an aggravating role in a variety
of diseases,3,4,6–8 and put fibrinogen forward as a potential
target in the treatment of chronic renal disease.
MATERIALS AND METHODS
Mice
C57BL/6J mice used in this study have a genetic deletion of the
fibrinogen A a-chain and lack all components of fibrinogen in the
circulation.45 In heterozygous mice, levels of circulating fibrinogen
are reduced to 70% (Supplementary Figure S1A online) but no
discernable differences were found in preliminary UUO studies
comparing Fibþ / and Fibþ /þ mice. Genotyping was done by PCR
of tail biopsy genomic DNA, as previously described.45 Female mice
were used because of animal availability. Unless otherwise indicated
experiments were performed at 10–12 weeks of age comparing /
to þ / littermates.
Unilateral ureteral obstruction
To induce UUO, mice were anesthetized with isoflurane and
underwent left proximal ureteral ligation via a midline abdominal
incision. The left ureter was ligated at two points with 4-0 silk and
dissected in between. Successful ureteral obstruction was later
confirmed by observation of dilation of the renal pelvis and
proximal ureter. Mice were killed and the kidneys were analyzed 7
(n¼ 12) and 14 days (n¼ 10) after UUO. Initial experiments
confirming renal fibrin(ogen) deposition during UUO were done in
wild-type littermates. All experimental procedures were in agree-
ment with the institutional and legislator regulations and approved
by the local authorities.
Histological and immunohistochemical stainings
Obstructed and contralateral kidneys were dissected, fixed in 4%
paraformaldehyde and embedded in paraffin, or frozen in liquid
nitrogen for cryosections. Sections (4 mm) were used for evaluation
of histological damage after hematoxylin/eosin and Sirius Red
staining and for immunohistochemistry. Immunohistochemistry
was performed using the following primary antibodies: Monoclonal
rabbit anti-mouse Ki67 (Thermo Scientific, Fremont, CA), mono-
clonal mouse anti-smooth muscle actin, clone 1A4, (Sigma-Aldrich,
St Louis, MO), polyclonal rabbit anti-human S100A4 (DakoCyto-
mation, Glostrup, Denmark), polyclonal goat anti-mouse Fibrino-
gen (Nordic Immunology, Tilburg, The Netherlands), monoclonal
rat anti-mouse CD45 (BD Pharmingen, BD Biosciences, Santa Cruz,
CA), monoclonal rat anti-mouse Ly-6B.2 (AbD Serotec, Oxford,
UK), monoclonal rat anti-mouse ER-TR7 (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), monoclonal rat anti-mouse F4/80
(BioLegend, San Diego, CA), and monoclonal rat anti-CD4 (kindly
provided by Dr A Dittrich, Hannover Medical School). Deparaffi-
nized kidney sections were boiled in citrate buffer for antigen
retrieval, blocked with 5% milk, and incubated overnight with
primary antibodies. This was followed by antibody visualization
using Alexa 488/Alexa 547 secondary antibody (Molecular Probes/
Invitrogen, Carlsbad, CA) or the ABC Vectastain kit (Vector
Laboratories, Burlingame, CA). Cell quantification was done by
counting of positive cells in 10 randomly chosen, non-overlapping
fields ( 200 magnification) using a LEICA DM2000, microscope
(Leica Microsystems, Bannockburn, IL). Some stainings were
analyzed by confocal laser-scanning microscopy using a TCS-SP2
AOBS with a PLAPO 63 1.4 objective (Leica Microsystems,
Wetzlar, Germany). Quantification of collagen fibers in Picrosirius
Red staining was done using polarized light microscopy and digital
image analysis (ImageJ software; National Institute of Health,
Bethesda, MD). Tubulointerstitial damage was quantified on
hematoxylin/eosin sections using an adapted scoring protocol
described by Adams et al.46 Damage was defined as broadening of
the basement membrane, tubular atrophy, and interstitial matrix
increase. Total damage in 10 randomly chosen, non-overlapping
fields ( 200 magnification) was defined as 0, no damage; 0.5,
damage of o25% of tubulointerstitial space; 1, damage of 26–50%
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of tubulointerstitial space; 2, damage of 51–75% of tubulointerstitial
space; 3, damage of 475% tubulointerstitial space.
Western blot
Western analysis was performed as previously described.47 After
electrophoresis, proteins were transferred to polyvinylidene difluor-
ide membranes, blocked with 5% milk in Tris-buffered saline
Tween-20, and probed overnight at 4 1C with primary antibodies:
fibrinogen, a-SMA (both described above); ICAM-1 (R&D Systems,
Minneapolis, MN), and collagen type I (Calbiochem, San Diego,
CA). Horseradish peroxidase-conjugated secondary antibodies were
purchased from Santa Cruz Biotechnology. Antibody binding was
visualized by chemiluminescence (SuperSignal West Pico Chemilu-
minescent; Thermo Scientific, Rockford, IL). Rabbit anti-mouse
glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Sigma-
Aldrich) was used as an internal loading control and for normali-
zation of protein quantification. Immunoblots were scanned and
quantified using ImageJ densitometry software.
Cell culture
Normal rat fibroblasts (NRK-49F; ATCC, Manassas, VA) were
cultured in Dulbecco’s modied Eagle’s medium (DMEM)/F12 with
10% fetal calf serum (FCS). For fibrinogen stimulation assays, cells
were thoroughly washed several times, incubated in DMEM/F12
without FCS for 6–8 h, and washed again before exposure to
fibrinogen (Dunn Labortechnik GmbH, Asbach, Germany). Fibri-
nogen was used at the indicated concentration or a standard
concentration of 1mg/ml and bovine serum albumin (Sigma-
Aldrich) was used at the same concentration as control. To evaluate
the effect of fibrinogen-deficient plasma, whole blood from Fib/
and Fibþ /þ mice was drawn into ammonium heparin-coated tubes
to obtain plasma after centrifugation. Plasma was diluted at 1:4 in
DMEM/F12 without FCS for cell stimulation. For laser scan
microscopy, cells were cultured on coverslips and fixed in methanol.
After standard immunocytochemistry with goat polyclonal fibro-
nectin (Santa Cruz Biotechnology) and monoclonal mouse anti-
smooth muscle actin, clone 1A4 (Sigma-Aldrich), coverslips were
mounted on slides and analyzed using a TCS-SP2 AOBS with
a PLAPO 63 1.4 objective (Leica Microsystems, Germany).
Immortalized murine proximal tubular epithelial cells (mPT) and
inner medullary collecting duct cells (IMCD3) were kindly provided
by Dr L Cantley (Yale School of Medicine, New Haven, CT). Primary
renal fibroblasts were cultured according to the method described
by Grimwood and Masterson48 using kidneys from MyD88-deficient
mice and wild-type control mice (kindly provided by Professor
T Sparwasser, TWINCORE Hannover, Germany).
Blocking peptides and antibodies
RGD peptide (Sigma-Aldrich) was used at a concentration of
40 mg/ml. Goat anti-rat ICAM-1 (R&D Systems) and hamster anti-
rat b-integrin antibodies (BD Pharmingen, San Diego, CA) were
used for blocking experiments at 5 mg/ml.
siRNA transfections
NRK-49F cells were transfected with siRNAs for ICAM-1 (Qiagen,
Hilden, Germany), TLR2 (Qiagen), TLR4 (Ambion Applied Biosys-
tems, Austin, TX), and MyD88 (Sigma-Aldrich) using TransIT
Transfection reagent (Mirus Bio LLC, Madison, WI) according to the
manufacturer’s instructions. Efficiency of specific siRNA knockdown
was confirmed by quantitative real-time PCR (Supplementary Figure
S1F online).
Proliferation assays
Proliferation of NRK-49F cells was measured using the Cell
Proliferation 5-bromodeoxyuridine (BrdU) ELISA kit according to
the manufacturer’s instructions (Roche Applied Science, Mannheim,
Germany). NRK-49F cells were thoroughly washed to wash off FCS-
derived fibrinogen, incubated in DMEM/F12 without FCS for 6–8 h,
and washed again before treatment with fibrinogen, the described
blocking peptide or antibody. The BrdU assay was performed
14–16 h later. After siRNA transfections, cells were thoroughly
washed and incubated in DMEM/F12 without FCS for 6–8 h.
Fibrinogen was added to the culture and the proliferation assay was
performed 14–16 h later. After BrdU incorporation for 2 h, the
monoclonal mouse-BrdU antibody (Clone BU-33, Sigma-Aldrich)
and the secondary donkey anti-mouse Alexa Flour488 antibody
(Molecular Probes, Eugene, OR) were used to visualize BrdU
labeling. Proliferation was quantified by counting BrdU-positive
cells in 10 randomly chosen, non-overlapping microscopic fields
after ( 200 magnification). Results were pooled from at least four
independent experiments.
Quantitative real-time PCR
RNA was isolated from treated NRK-49F cells and frozen kidney
tissue using the RNeasy Mini kit (Qiagen) according to the
manufacturer’s instructions. Reverse transcription was performed
with M-MLV-Reverse Transcriptase (Promega, Madison, WI) and
random primers. Amplified cDNA was used as a template for
quantitative real-time PCR. The levels of a-SMAwere determined by
quantitative real-time PCR using a Roche Lightcycler 480 System
with SYBR green master mix and specific primers: a-SMA for: 50-GT
GCTATGTCGCTCTGGACTTTGA-30; a-SMA rev: 50-ATGAAAGAT
GGCTGGAAGAGGGTC-30; TLR2 for: 50-GGCCACAGGACTCAAG
AGCA-30; TLR2 rev: 50-CTGGGCAGAATGGCCTTCCC-30; TLR4
for: 50-AGATCTGAGCTTCAACCCCCTGA-30; TLR4 rev: 50-CCATG
CCATGCCTTGTCTTCA-30; ICAM-1 for :50-TCGGCTTCTGCCA
CCATCAC-30; ICAM-1 rev: 50-TCATTCCCACGGAGCAGCAC-30;
MyD88 for: 50-GAGATCCGCGAGTTTGAGAC-30; MyD88 rev: 50-T
TGTCTGTGGGACACTGCTC-30; Actin for: 50-AGCCATGTACGTA
GCCATCC-30; Actin rev: 50-CTCTCAGCTGTGGTGGTAA-30. Melting
curves were examined to verify that a single product was amplified.
For quantitative analysis, relative mRNA levels were calculated
according to the 2DDCt method;49 all samples were normalized to
actin gene expression.
Statistical analysis
Data are shown as mean±s.d. and were compared by Student’s
t-test or for multiple groups by analysis of variance, followed by
Dunnett’s or Bonferroni post hoc tests. Data analysis was performed
using Excel statistical software and Prism 4.0 (GraphPad
Software, San Diego, CA). Statistical differences were accepted when
P was o0.05.
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
We greatly appreciate the technical assistance of H Richi and M Kuhls.
This study has been supported by grants from the Deutsche
Forschungsgemeinschaft SCHM2146/3-1 and by the Dr Werner-
Jacksta¨dt Foundation (Junior Excellence Research Group Grant). Part
of this work has been presented as an oral communication at the ASN
Renal Week 2010 in Denver.
Kidney International (2011) 80, 1035–1044 1043
I So¨rensen et al.: Fibrinogen in renal fibrosis o r ig ina l a r t i c l e
SUPPLEMENTARY MATERIAL
Figure S1. In vivo and in vitro effects of fibrinogen on tubular and
interstitial cells.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
REFERENCES
1. Clark RA. Fibrin is a many splendored thing. J Invest Dermatol 2003; 121:
xxi–xxii.
2. Laurens N, Koolwijk P, de Maat MP. Fibrin structure and wound healing.
J Thromb Haemost 2006; 4: 932–939.
3. Flick MJ, LaJeunesse CM, Talmage KE et al. Fibrin(ogen) exacerbates
inflammatory joint disease through a mechanism linked to
the integrin alphaMbeta2 binding motif. J Clin Invest 2007; 117:
3224–3235.
4. Paul J, Strickland S, Melchor JP. Fibrin deposition accelerates
neurovascular damage and neuroinflammation in mouse models of
Alzheimer’s disease. J Exp Med 2007; 204: 1999–2008.
5. Drew AF, Liu H, Davidson JM et al. Wound-healing defects in mice lacking
fibrinogen. Blood 2001; 97: 3691–3698.
6. de Giorgio-Miller A, Bottoms S, Laurent G et al. Fibrin-induced skin fibrosis
in mice deficient in tissue plasminogen activator. Am J Pathol 2005; 167:
721–732.
7. Masamune A, Kikuta K, Watanabe T et al. Fibrinogen induces cytokine
and collagen production in pancreatic stellate cells. Gut 2009; 58:
550–559.
8. Vidal B, Serrano AL, Tjwa M et al. Fibrinogen drives dystrophic muscle
fibrosis via a TGFbeta/alternative macrophage activation pathway. Genes
Dev 2008; 22: 1747–1752.
9. Hewitson TD. Renal tubulointerstitial fibrosis: common but never simple.
Am J Physiol Renal Physiol 2009; 296: F1239–F1244.
10. Kincaid-Smith P. Coagulation and renal disease. Kidney Int 1972; 2:
183–190.
11. Bruno NE, Yano Y, Takei Y et al. Immune complex-mediated
glomerulonephritis is ameliorated by thrombin-activatable fibrinolysis
inhibitor deficiency. Thromb Haemost 2008; 100: 90–100.
12. Shin JI, Park JM, Shin YH et al. Role of mesangial fibrinogen deposition in
the pathogenesis of crescentic Henoch-Schonlein nephritis in children.
J Clin Pathol 2005; 58: 1147–1151.
13. Drew AF, Tucker HL, Liu H et al. Crescentic glomerulonephritis is
diminished in fibrinogen-deficient mice. Am J Physiol Renal Physiol 2001;
281: F1157–F1163.
14. Yamaguchi I, Lopez-Guisa JM, Cai X et al. Endogenous urokinase lacks
antifibrotic activity during progressive renal injury. Am J Physiol Renal
Physiol 2007; 293: F12–F19.
15. Eddy AA. Serine proteases, inhibitors and receptors in renal fibrosis.
Thromb Haemost 2009; 101: 656–664.
16. Iwano M, Plieth D, Danoff TM et al. Evidence that fibroblasts
derive from epithelium during tissue fibrosis. J Clin Invest 2002; 110:
341–350.
17. Le Hir M, Hegyi I, Cueni-Loffing D et al. Characterization of renal
interstitial fibroblast-specific protein 1/S100A4-positive cells in
healthy and inflamed rodent kidneys. Histochem Cell Biol 2005; 123:
335–346.
18. Tsujie M, Isaka Y, Ando Y et al. Gene transfer targeting interstitial
fibroblasts by the artificial viral envelope-type hemagglutinating virus of
Japan liposome method. Kidney Int 2000; 57: 1973–1980.
19. Grgic I, Kiss E, Kaistha BP et al. Renal fibrosis is attenuated by targeted
disruption of KCa3.1 potassium channels. Proc Natl Acad Sci USA 2009;
106: 14518–14523.
20. Picard N, Baum O, Vogetseder A et al. Origin of renal myofibroblasts in
the model of unilateral ureter obstruction in the rat. Histochem Cell Biol
2008; 130: 141–155.
21. Gardiner EE, D’Souza SE. A mitogenic action for fibrinogen mediated
through intercellular adhesion molecule-1. J Biol Chem 1997; 272:
15474–15480.
22. Hao S, Shen H, Hou Y et al. tPA is a potent mitogen for renal interstitial
fibroblasts: role of beta1 integrin/focal adhesion kinase signaling. Am J
Pathol 2010; 177: 1164–1175.
23. Li Y, Tan X, Dai C et al. Inhibition of integrin-linked kinase attenuates renal
interstitial fibrosis. J Am Soc Nephrol 2009; 20: 1907–1918.
24. Pulskens WP, Rampanelli E, Teske GJ et al. TLR4 promotes fibrosis but
attenuates tubular damage in progressive renal injury. J Am Soc Nephrol
2010; 21: 1299–1308.
25. Campbell MT, Hile KL, Zhang H et al. Toll-like receptor 4: a novel signaling
pathway during renal fibrogenesis. J Surg Res 2009.
26. Anders HJ. Toll-like receptors and danger signaling in kidney injury. J Am
Soc Nephrol 2010; 21: 1270–1274.
27. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage
chemokine secretion through toll-like receptor 4. J Immunol 2001; 167:
2887–2894.
28. Pierer M, Rethage J, Seibl R et al. Chemokine secretion of rheumatoid
arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands.
J Immunol 2004; 172: 1256–1265.
29. Leemans JC, Butter LM, Pulskens WP et al. The role of Toll-like receptor 2
in inflammation and fibrosis during progressive renal injury. PLoS One
2009; 4: e5704.
30. Matsushita Y, Hasegawa M, Matsushita T et al. Intercellular adhesion
molecule-1 deficiency attenuates the development of skin fibrosis in
tight-skin mice. J Immunol 2007; 179: 698–707.
31. Ruppert C, Markart P, Wygrecka M et al. Role of coagulation and
fibrinolysis in lung and renal fibrosis. Hamostaseologie 2008; 28: 30–32,
34-36.
32. Boyd JH, Chau EH, Tokunanga C et al. Fibrinogen decreases
cardiomyocyte contractility through an ICAM-1-dependent mechanism.
Crit Care 2008; 12: R2.
33. Patibandla PK, Tyagi N, Dean WL et al. Fibrinogen induces alterations
of endothelial cell tight junction proteins. J Cell Physiol 2009; 221: 195–203.
34. Ramila D, Ardura JA, Esteban V et al. Parathyroid hormone-related protein
promotes inflammation in the kidney with an obstructed ureter. Kidney
Int 2008; 73: 835–847.
35. Chow FY, Nikolic-Paterson DJ, Ozols E et al. Intercellular adhesion
molecule-1 deficiency is protective against nephropathy in type 2
diabetic db/db mice. J Am Soc Nephrol 2005; 16: 1711–1722.
36. Janssen U, Ostendorf T, Gaertner S et al. Improved survival and
amelioration of nephrotoxic nephritis in intercellular adhesion molecule-1
knockout mice. J Am Soc Nephrol 1998; 9: 1805–1814.
37. Motojima M, Matsusaka T, Kon V et al. Fibrinogen that appears in
Bowman’s space of proteinuric kidneys in vivo activates podocyte
Toll-like receptors 2 and 4 in vitro. Nephron Exp Nephrol 2010; 114: e39–e47.
38. Gluba A, Banach M, Hannam S et al. The role of Toll-like receptors in renal
diseases. Nat Rev Nephrol 2010; 6: 224–235.
39. Chowdhury P, Sacks SH, Sheerin NS. Endogenous ligands for TLR2 and
TLR4 are not involved in renal injury following ureteric obstruction.
Nephron Exp Nephrol 2010; 115: e122–e130.
40. Tang L, Ugarova TP, Plow EF et al. Molecular determinants of acute
inflammatory responses to biomaterials. J Clin Invest 1996; 97:
1329–1334.
41. Hattori N, Degen JL, Sisson TH et al. Bleomycin-induced
pulmonary fibrosis in fibrinogen-null mice. J Clin Invest 2000; 106:
1341–1350.
42. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb
Haemost 2003; 89: 601–609.
43. Bash LD, Erlinger TP, Coresh J et al. Inflammation, hemostasis, and the risk
of kidney function decline in the Atherosclerosis Risk in Communities
(ARIC) Study. Am J Kidney Dis 2009; 53: 596–605.
44. Fried L, Solomon C, Shlipak M et al. Inflammatory and prothrombotic
markers and the progression of renal disease in elderly individuals. J Am
Soc Nephrol 2004; 15: 3184–3191.
45. Suh TT, Holmback K, Jensen NJ et al. Resolution of spontaneous bleeding
events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev
1995; 9: 2020–2033.
46. Adams J, Kiss E, Arroyo AB et al. 13-cis retinoic acid inhibits development
and progression of chronic allograft nephropathy. Am J Pathol 2005; 167:
285–298.
47. Schmitt R, Marlier A, Cantley LG. Zag expression during aging suppresses
proliferation after kidney injury. J Am Soc Nephrol 2008; 19: 2375–2383.
48. Grimwood L, Masterson R. Propagation and culture of renal fibroblasts.
Methods Mol Biol 2009; 466: 25–37.
49. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods
2001; 25: 402–408.
1044 Kidney International (2011) 80, 1035–1044
or ig ina l a r t i c l e I So¨rensen et al.: Fibrinogen in renal fibrosis
